Free beta access. 5 free AI tokens each week. Optional top-ups available. See what is included
Opening Word document…

Funding extremely high totaling over 40 billion

BioSpace 22 [BioSpace Editorial Staff 9/21/2020 ; The Home of the Life Sciences Industry. Find biotech, clinical research and pharmaceutical jobs from thousands of employers; “Investment in Biopharma is Reaching an Inflection Point,” https://www.biospace.com/article/investment-in-biopharma-is-reaching-an-inflection-point-/]

Emerging biopharma companies are vital to the creation of many novel therapies and health technologies, and play an important role in the future of early-stage drug development. Little wonder U.S.-based biotech companies are the darling of private equity, venture capital companies and institutional money managers.

During the past two years, fundraising and investment in biotechnology have reached record levels. These factors have translated into elevated IPO activity and an overarching positive outlook.

Private investments have been led by healthtech and biopharma, and the first half of 2020 saw a general year-over-year increase in biotech investment. The surge was led by 26 financings of $100 million plus, totaling more than $5 billion. The first quarter of 2021, on the other hand, climbed to a record $23.4 billion in private investments, beating out the quarterly record set in Q3 2020 by 56%. This momentum continued into the second quarter of 2021 with total investment in healthtech and biopharma equalling $23.9 billion.

According to data from IQVIA, around 80% of the industry's drug development pipeline comes from emerging biopharma companies, which means small companies are the most influential in developing innovative new therapies. Emerging biopharma companies account for 84% of worldwide early-stage R&D and 73% of late-stage research.

In 2020, VC activity in biotech grew by 45%, bringing the global total to $36.6 billion USD, and the U.S. led the way.

Sign in to recut, update, or save this card.